On November 4, 2024 ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA),an AI-driven biotherapeutic research and technology company, reported the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts (Press release, ImmunoPrecise Antibodies, NOV 4, 2024, View Source [SID1234647660]). This exclusive gathering will highlight IPA’s latest advancements in AI-driven design, biologics innovation, and strategic technological developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights of TECHDAY:

•
Presentation by Dr. Dirk Van Hyfte: Dr. Van Hyfte will present "Accelerating Drug Discovery with LENSai: A Comprehensive Solution." He will showcase LENSai, BioStrand’s revolutionary platform, and discuss how it transforms drug discovery by integrating biotechnology, biotherapeutics, and artificial intelligence. Key topics include using HYFT Universal Fingerprints to revolutionize multi-omics and data integration while accelerating drug discovery, development and optimization with AI-driven insights.
•
LENSai Demo: A live demonstration of the LENSai platform, showcasing its capabilities in accelerating and enhancing the discovery and design of therapeutic antibodies through AI-driven insights.
•
Presentation by Dr. Shuji Sato: Dr. Sato will present IPA’s B Cell Discovery Platform and discuss its integration with the company’s advanced AI and NGS workflows for highly efficient hit expansion. This process includes:
•
Fast analysis of complete NGS repertoires
•
Multimodal feature extraction that combines sequence, structure, and large language model (LLM) embeddings to deliver enhanced insights into sample diversity.
•
Add-ons that complement outputs from phage display, B-cell, and hybridoma technologies, enabling the retrieval of antibody sequences with characteristics similar to known binders.
•
Fireside Chat: Disruptive Dialogue: Empowering Drug Discovery Through Seamless Data Integration and AI-Powered Insights

Participants:

•
Dr. Dirk Van Hyfte, Head of Innovation and Co-founder, BioStrand (IPA)
•
Jeff Fried, Director of Platform Strategy and Innovation, InterSystems

This discussion will explore how vector search intelligence is at the core of the LENSai platform, seamlessly integrated with the InterSystems IRIS data platform to deliver precise, scalable solutions that accelerate antibody discovery, enhance accuracy, and increase candidate diversity.

AI-Driven Drug Discovery Summit USA 2024

Additionally, earlier that same week at the AI-Driven Drug Discovery Summit USA 2024, IPA will participate in another fireside chat titled Beyond conventional biologics: the intersection of machine learning and biological engineering to invent.

Participants at the AI-Driven Drug Discovery Summit USA 2024:

•
Adam Root, Vice President and Head of Protein Sciences, Generate Biomedicines
•
Dr. Dirk Van Hyfte, Head of Innovation and Co-founder, BioStrand (IPA)

The chat will focus on the integration of artificial intelligence and machine learning with wet lab infrastructure to accelerate biologics development.

A recorded webcast of the TECHDAY presentations will be available in the Investors section of the IPA website under "Events and Presentations" at ir.ipatherapeutics.com.

On November 4, 2024 Lomond Therapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies, reported the completion of a reverse merger transaction with Venetian-1 Acquisition Corp. and the closing of a $44 million private placement financing (Press release, Lomond Therapeutics, NOV 4, 2024, View Source [SID1234647679]). Following the reverse merger, Venetian-1 Acquisition Corp. changed its name to Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics" or the "Company"), and will continue the historic and innovative business of Lomond Therapeutics, Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This transaction provides the resources necessary to advance our potentially best-in-class programs, lomonitinib, lonitoclax and our menin inhibitor, through clinical development," said Iain Dukes, M.A. D.Phil., co-founder and chief executive officer at Lomond Therapeutics. "Lomonitinib is currently being evaluated in a Phase 1b clinical trial in patients with mutated FLT3 relapsed refractory AML – an area of important unmet need and will shortly commence recruitment of CLL and selected lymphoma patients to evaluate lonitoclax, a potentially first-in-class oral targeted selective B-cell lymphoma-2 ("BCL-2-2") inhibitor."

The Company announced that current investors, OrbiMed and Torrey Pines Investment have participated in the placement alongside new investors led by Deerfield Management Company, American Financial Group, Heights Capital and others.

Previous members of Lomond Therapeutics, Inc.’s board of directors, Carl L. Gordon Ph.D., CFA, Iain Dukes M.A., D.Phil., Nikolay Savchuk Ph.D., and Eddie Wang Rodriguez J.D., will continue as directors of the Company.

The offering was exempt from registration under Section 4(a)(2) of the United States Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated by the U.S. Securities and Exchange Commission ("SEC") thereunder. The Common Stock in the offering was sold to "accredited investors," as defined in Regulation D, and was conducted on a "reasonable best efforts" basis.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Raymond James and Wedbush & Co. acted as the placement agents and Venetian-1 Acquisition Corp. was formed by Montrose Capital, which sponsored the transaction.

On November 4, 2024 BioNTech reported third quarter 2024 financial results and corporate update (Presentation, BioNTech, NOV 4, 2024, View Source [SID1234648706]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 4, 2024 Caszyme, a pioneer in the development and application of CRISPR gene editing technology, and Integra Therapeutics, a company leading the way in creating advanced therapies based on next-generation gene-writing tools, reported a licensing agreement for the use of Caszyme’s novel Cas12l nucleases to develop safer and more efficient gene and cell therapies (Press release, Integra Therapeutics, NOV 4, 2024, View Source [SID1234654539]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement was unveiled at this year’s BIO Europe, which is the largest partnering event for the biomedical industry in Europe, taking place this week in Stockholm. Over 2,800 companies attended from 60 countries, with more than 5,000 biopharma professionals in attendance.

Under the agreement, Integra Therapeutics will incorporate the genome editor Cas12l into its FiCAT 2.0 (Find and Cut-And-Transfer) gene-writing platform, following successful in vivo and ex vivo studies, which yielded highly positive results in terms of safety and functionality in human cells. Caszyme will receive milestone payments up to 40 million. euros in addition to royalties on sales.

Cas12l is a unique CRISPR nuclease family with an effector size of approximately 850 amino acids that stands out for its small size and versatility. As the demand for efficient and safe gene-editing tools in therapeutic contexts continues to grow, these small nucleases represent a promising solution, combining efficacy with the practical advantages of reduced size. Caszyme-developed Cas12l shows great activity in human cells across multiple targets.

Compared to other nucleases, Caszyme’s Cas12l offers additional delivery possibilities, especially when combined with other effector domains. Moreover, smaller nucleases from non-pathogenic bacteria may be less immunogenic compared to their larger counterparts, further highlighting their therapeutic potential. The nucleases discovered by Caszyme exhibit different characteristics from Cas9 nucleases, which formed the foundation of the find module in FiCAT 1.0, expanding their potential applications in advanced therapies.

"Caszyme’s goal is to enable therapeutic companies to develop novel, efficient and affordable gene editing modalities. This collaboration with Integra Therapeutics is a perfect alignment between two highly innovative European companies, and when successful, will help bring advanced gene editing based therapies to the market." said Dr Monika Paulė, CEO and Co-Founder of Caszyme.

Adding, Dr Giedrius Gasiunas, CSO and Co-Founder of Caszyme, said "the partnership will further Caszyme’s core scientific aims – which are to develop novel, safer and smaller Cas12l nucleases that are more compatible with diverse delivery technologies, such as AAVs, mRNA and LNPs."

Dr Avencia Sánchez-Mejías, CEO and Co-Founder of Integra Therapeutics, added, "This agreement with Caszyme reaffirms our commitment with the excellence in technology development to delivery therapeutic solutions for patients with our gene-writing technology in the preclinical regulatory phase and highlights the success of the transnational project funded by the European Commission, which we launched in 2022 through Eurostars, in support of Europe’s most innovative SMEs."

"The integration of Caszyme nucleases into our FiCAT 2.0 platform strengthens Integra Therapeutics’ mission to develop the highest-quality gene and cell therapy products for the treatment of a wide range of genetic and oncological diseases. FiCAT 2.0 will set itself apart in the market by offering enhanced precision and efficiency," explained Dr Marc Güell, CSO and Co-Founder of Integra Therapeutics.

On November 4, 2024 Neogap Therapeutics, a Swedish clinical-stage biotechnology company, reported that it has entered a strategic collaboration with NorthX Biologics, a leading CDMO, to advance manufacturing strategies for Neogap’s personalised cancer cell therapy (Press release, Neogap Therapeutics, NOV 4, 2024, View Source [SID1234647663]). Supported by ongoing funding from the European Innovation Council (EIC) Accelerator, the partnership aims to optimise and scale production for future clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neogap Therapeutics develops pTTL (personalised Tumour Trained Lymphocytes), a cell therapy designed to treat solid tumours by training the immune system to recognise and attack cancer cells through the patient’s unique neoantigens. Currently, pTTL is under evaluation in a Phase I/II clinical trial focused on assessing its safety and tolerability in patients with advanced colorectal cancer.

The collaboration, carried out within the framework of the EIC Accelerator program, aims to establish a robust, cost-effective production setup that enhances both productivity and scalability.

The project includes a comprehensive analysis of Neogap’s manufacturing protocols, with a focus on scale-out strategies and GMP process industrialisation to support large-scale clinical trials and eventual commercialisation. The goal is to implement streamlined production processes and logistics, increasing resilience and cost-effectiveness as Neogap progresses toward broader clinical applications and greater patient access.

Samuel Svensson, CEO of Neogap Therapeutics, comments: "Partnering with NorthX Biologics is an important step in preparing our therapy for future trials beyond the current Phase 1 study. Establishing a reliable and cost-effective manufacturing process is key to our clinical and commercial goals. We’re excited for our team to work closely with NorthX’s experts, combining our strengths to develop a scalable solution that will allow us to treat a larger patient population as we advance."

Janet Hoogstraate, CEO of NorthX Biologics, comments: "At NorthX Biologics, we are proud to be ‘beyond CDMO’ – a proactive partner that actively contributes to the development of future medicines by collaborating with innovative companies like Neogap Therapeutics. Through our close partnership, we leverage our expertise and Innovation Hub to support at every stage, from initial concept to scalable production of pioneering cell therapies. Together, we are driving groundbreaking innovations forward to improve patients’ lives around the world."